2,3-Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin B1 receptor antagonists.

Feng, Dong-Mei; Wai, Jenny M; Kuduk, Scott D; Ng, Christina; Murphy, Kathy L; Ransom, Richard W; Reiss, Duane; Chang, Raymond S L; Harrell, Charles M; MacNeil, Tanya; Tang, Cuyue; Prueksaritanont, Thomayant; Freidinger, Roger M; Pettibone, Douglas J; Bock, Mark G

Feng, Dong-Mei; Wai, Jenny M; Kuduk, Scott D; Ng, Christina; Murphy, Kathy L; Ransom, Richard W; Reiss, Duane; Chang, Raymond S L; Harrell, Charles M; MacNeil, Tanya; Tang, Cuyue; Prueksaritanont, Thomayant; Freidinger, Roger M; Pettibone, Douglas J; Bock, Mark G.

Afiliação

Feng DM; Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA. dongmei_feng@merck.com

Bioorg Med Chem Lett ; 15(9): 2385-8, 2005 May 02.

Article em En | MEDLINE | ID: mdl-15837330

RESUMO

A novel class of 2,3-diaminopyridine bradykinin B1 receptor antagonists is disclosed. Structure-activity relationship studies (SARs) that led to compounds with significantly improved potency and pharmacokinetic properties relative to the lead compound are described.

Assuntos

Aminopiridinas/farmacologia; Antagonistas de Receptor B1 da Bradicinina; Piridinas/síntese química; Aminopiridinas/química; Desenho de Fármacos; Humanos; Cinética; Modelos Moleculares; Piridinas/farmacologia; Relação Estrutura-Atividade

Buscar no Google

Imprimir

XML

PubMed Links

Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piridinas / Antagonistas de Receptor B1 da Bradicinina / Aminopiridinas Limite: Humans Idioma: En Revista: Bioorg Med Chem Lett Ano de publicação: 2005 Tipo de documento: Article

Buscar no Google

Imprimir

XML

PubMed Links